Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria-Reference-Cited by-同舟云学术

Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria

Published:2019-11-22 Issue:8 Volume:26 Page:1846-1855
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Matos Ignacio,Martin-Liberal Juan,García-Ruiz Alonso^ORCID,Hierro Cinta,Ochoa de Olza Maria,Viaplana Cristina,Azaro Analia,Vieito Maria,Braña Irene^ORCID,Mur Gemma,Ros Javier,Mateos Jose,Villacampa Guillermo,Berché Roger,Oliveira Mafalda^ORCID,Alsina Maria,Elez Elena,Oaknin Ana,Muñoz-Couselo Eva,Carles Joan,Felip Enriqueta,Rodón Jordi,Tabernero Josep^ORCID,Dienstmann Rodrigo,Perez-Lopez Raquel,Garralda Elena

Funder

BBVA Foundation

la Caixa

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predominance of hyperprogression in mucosal melanoma during anti-PD-1 monotherapy treatment;The Oncologist;2024-08-20

2. Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution;International Journal of Clinical Oncology;2024-06-08

3. Fc–Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies;Journal for ImmunoTherapy of Cancer;2024-06

4. Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy;Clinical Lung Cancer;2024-06

5. Advancements in neoadjuvant immune checkpoint inhibitor therapy for locally advanced head and neck squamous Carcinoma: A narrative review;International Immunopharmacology;2024-06